CodeBreak 100: results show durability of clinical benefit with sotorasib in patients with non-small cell lung cancer - Onco Americas
The Discovery Of Amgen's Novel Investigational KRAS(G12C) Inhibitor AMG 510 Published In Nature
Amgen unveils its KRas inhibitor in human clinical trials
SHP2 and SOS1 Targets: Additional Players in the KRAS Inhibitors Race?
Understanding the influence of AMG 510 on the structure of KRASG12C empowered by molecular dynamics simulation - ScienceDirect
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity | Nature
The Discovery Of Amgen's Novel Investigational KRASG12C Inhibitor AMG 510
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity | Nature
Enhanced binding of AMG 510 to KRAS(G12C) results in improved... | Download Scientific Diagram
Amgen unveils its KRas inhibitor in human clinical trials
KRAS(G12C)–AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations | Scientific Reports
Ongoing clinical trials involving direct targeting of KRAS. | Download Scientific Diagram
The Discovery Of Amgen's Novel Investigational KRAS(G12C) Inhibitor AMG 510 Published In Nature
The Discovery Of Amgen's Novel Investigational KRAS(G12C) Inhibitor AMG 510 Published In Nature
Asco 2019 – KRAS chase heats up with Amgen data | Evaluate
Amgen's AMG 510 Targeted Cancer Therapy (NASDAQ:AMGN) | Seeking Alpha
AMG 510 inhibits tumour growth of patient-derived xenografts, and... | Download Scientific Diagram
Sotorasib: a KRASG12C inhibitor for non-small cell lung cancer: Trends in Pharmacological Sciences
Frontiers | Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
AMG 510 inhibits KRAS(G12C) signalling and impairs viability a,... | Download Scientific Diagram
Cancers | Free Full-Text | Targeting KRAS in Cancer: Promising Therapeutic Strategies
Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors | Journal of Medicinal Chemistry
Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes | npj Precision Oncology
